Navigation Links
Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
Date:9/9/2009

BRIDGEWATER, England, September 9 /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +44(0)908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com



'/>"/>
SOURCE Clinical Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Akaza Research to Present OpenClinica 3.0 at Upcoming Clinical Research Conferences: SoCRA, SCDM
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
5. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
6. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
7. Clinical Trials Offices Changing Academic Health Center Research Infrastructure
8. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
9. goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites
10. Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study
11. Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017 In today,s pre-market research, ... Intrexon Corp. (NYSE: XON), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), ... According an article on Barron,s, Credit Suisse upgraded its rating ... March 21 st , 2017. These stocks research reports can ... ...
(Date:3/29/2017)... March 29, 2017 Patients are the most ... CSL Behring awards Local Empowerment for Advocacy Development (LEAD) ... groups. These groups tackle complex legislative and public policy ... Hill and in statehouses across the U.S. ... was awarded to New England Hemophilia Association (NEHA), Neuropathy ...
(Date:3/29/2017)... /PRNewswire/ - Last year,s petition to the White House signed ... active to generate awareness on the importance of new organic medicines ... healthcare market place. ... Earlier this month Health Advance (OTC PINK: ... nutritional products, announced its endeavors on this generally recognized as ...
(Date:3/29/2017)... CA, USA (PRWEB) , ... March 29, 2017 , ... ... various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 venue and ... the Omni Parker House Hotel, in Boston, MA. , The Omni Parker House Hotel, ...
Breaking Biology Technology:
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
Breaking Biology News(10 mins):